ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

11 links10 made here, not in the record11 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07021911Concomitant Radiotherapyand New Drugs in MetastaticBreast CancerFondazione Policlinico UniversrecruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · ExposureExposureTrastuzumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · ExposureExposureAtezolizumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposurePertuzumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureTrastuzumab deruxtecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposurePalbociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureRibociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureAbemaciclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureSacituzumab govitecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureAdo-Trastuzumab EmtansineMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · ExposureExposure

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

Made here1 judgment on this link
NCT07021911gives it, found by reading the recordPembrolizumabDefined by Claude Opus 5.5Nov 1, 2026, 8:22 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Pembrolizumabmade hereClaude Opus 5.5ExposureCurrent
Nov 2Trastuzumabmade hereClaude Opus 5.5ExposureCurrent
Nov 3Atezolizumabmade hereClaude Opus 5.5ExposureCurrent
Nov 3Pertuzumabmade hereClaude Opus 5.5ExposureCurrent
Nov 3Trastuzumab deruxtecanmade hereClaude Opus 5.5ExposureCurrent
Nov 3Palbociclibmade hereClaude Opus 5.5ExposureCurrent
Nov 3Ribociclibmade hereClaude Opus 5.5ExposureCurrent
Nov 3Abemaciclibmade hereClaude Opus 5.5ExposureCurrent
Nov 3Sacituzumab govitecanmade hereClaude Opus 5.5ExposureCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10Ado-Trastuzumab Emtansinemade hereClaude Opus 5.5ExposureCurrent
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.